Janssen Biotech, Inc.

New York University

Surrozen Operating, Inc.

Janssen Pharmaceuticals, Inc.

Biocerox Products B.v.

Randall J Brezski

William Strohl

Robert Jordan

Yang Li

Jinquan Luo

Wen-Chen Yeh

Victor J Torres

Helene Baribault

Peter T Buckley

Anthony S Lynch

David M Knight

Aaron Sato

Mark Chiu

Mary Ryan

Brian Whitaker

Louis Boon

Petrus Johannes Simons

Tom Zhiye Yuan

Claudia Yvonne Janda

Chenggang Lu

Kuo-Pao Lai

Monica Goldberg

Keri Dorn

Michelle Kinder

Diane Petrone

Tristan William Fowler

Sheng-Jiun Wu

Thomas J Malia

Shengjiang Tu

Leonard Presta

Zhengjian Zhang

Thomas Lopez

Liqin Xie

Jeffrey Fernandez

Hui Chen

The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.

Wnt surrogate molecules and uses thereof

The present disclosure provides liver-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in liver tissues and treat liver diseases and disorders.

Liver-specific Wnt signal enhancing molecules and uses thereof

WNT surrogate molecules and uses thereof

The present disclosure is directed to staphylococcal leukotoxin and hemolysin binding molecules and fusion constructs. The present disclosure is further directed to methods of treating, preventing, and diagnosing staphylococcal infection in a subject using the binding molecules and fusion constructs described herein.

Compositions and methods for anti-staphylococcal biologic agents

The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.

Humanized anti-CD134 (OX40) antibodies and uses thereof

The present application generally relates to multi-specific molecules that bind to multiple bacterial virulence factors, methods for producing these binding molecules, and the use of these binding molecules to treat bacterial infections. In particular, the binding molecules comprise at least two binding domains, preferably an antibody or antibody fragment and an alternative scaffold. The first binding domain is capable of binding to a glycosylated staphylococcal surface protein, preferably an SDR-containing protein. The second binding domain is capable of binding to a staphylococcal leukotoxin, preferably LukAB, LukD or LukE. These multi-specific binding compounds have killing activity against staphylococci and, thus, can be used in the treatment and/or amelioration of ainfection, including methicillin-resistant

Compositions and methods for phagocyte delivery of anti-staphylococcal agents

The present invention relates to modified Fc-containing molecules including modified antibodies characterized by increased resistance to host and pathogen-derived proteases, ability to interact with Fc&#x3b3;R receptors except with Fc&#x3b3;RI, and lack of induction of IL-10 secretion by macrophages, and methods of using and making them.

Active protease-resistant antibody FC mutants

The invention relates to antibody compositions and use of the composition to detect disease processes associated with elaboration of proteases. The reagents are directed to assessing an IgG breakdown product that is the result of such proteolytic cleavage. The invention further relates to the use of a therapeutic immunospecific for IgG protease cleavage products to restore effector function to antibody compositions that are subject to protease cleavage.

Immunoglobulin cleavage fragments and disease indicators and compositions for detecting and binding such

Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such

Growing community of inventors

Alameda, CA, United States of America

Randall J Brezski